SE9500778D0 - Process for producing a protein - Google Patents

Process for producing a protein

Info

Publication number
SE9500778D0
SE9500778D0 SE9500778A SE9500778A SE9500778D0 SE 9500778 D0 SE9500778 D0 SE 9500778D0 SE 9500778 A SE9500778 A SE 9500778A SE 9500778 A SE9500778 A SE 9500778A SE 9500778 D0 SE9500778 D0 SE 9500778D0
Authority
SE
Sweden
Prior art keywords
apoe
apoa
matrix
endotoxins
aqueous solution
Prior art date
Application number
SE9500778A
Other languages
English (en)
Inventor
Hans Ageland
Lena Romander
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9500778A priority Critical patent/SE9500778D0/sv
Publication of SE9500778D0 publication Critical patent/SE9500778D0/sv
Priority to IL11732096A priority patent/IL117320A/en
Priority to AT96906136T priority patent/ATE240348T1/de
Priority to EP96906136A priority patent/EP0813541B1/en
Priority to JP8526799A priority patent/JPH11501046A/ja
Priority to AU49607/96A priority patent/AU694623B2/en
Priority to NZ303325A priority patent/NZ303325A/xx
Priority to DK96906136T priority patent/DK0813541T3/da
Priority to DE69628148T priority patent/DE69628148T2/de
Priority to ZA961679A priority patent/ZA961679B/xx
Priority to PT96906136T priority patent/PT813541E/pt
Priority to ES96906136T priority patent/ES2199284T3/es
Priority to CA002212125A priority patent/CA2212125A1/en
Priority to US08/875,125 priority patent/US5834596A/en
Priority to PCT/SE1996/000271 priority patent/WO1996027608A1/en
Priority to US09/129,720 priority patent/US5990081A/en
Priority to US09/444,816 priority patent/US6506879B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SE9500778A 1995-03-03 1995-03-03 Process for producing a protein SE9500778D0 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9500778A SE9500778D0 (sv) 1995-03-03 1995-03-03 Process for producing a protein
IL11732096A IL117320A (en) 1995-03-03 1996-02-29 PROCESS FOR PURIFYING APOLIPOPROTEINS ApoA AND ApoE OR MIXTURES THEREOF, SUBSTANTIALLY ENDOTOXIN-FREE ApoA OR ApoE PRODUCED BY THIS PROCESS AND THE USE OF APOLIPOPROTEINS PRODUCED BY THIS PROCESS IN THE PREPARATION OF A MEDICAMENT
PCT/SE1996/000271 WO1996027608A1 (en) 1995-03-03 1996-03-01 Process for producing a protein
NZ303325A NZ303325A (en) 1995-03-03 1996-03-01 Preparation of an endotoxin-free apolipoprotein a or apolipoprotein e
ZA961679A ZA961679B (en) 1995-03-03 1996-03-01 Process for producing a protein
JP8526799A JPH11501046A (ja) 1995-03-03 1996-03-01 タンパク質の製造法
AU49607/96A AU694623B2 (en) 1995-03-03 1996-03-01 Process for producing a protein
AT96906136T ATE240348T1 (de) 1995-03-03 1996-03-01 Verfahren zur herstellung eines proteins
DK96906136T DK0813541T3 (da) 1995-03-03 1996-03-01 Fremgangsmåde til fremstilling af et protein
DE69628148T DE69628148T2 (de) 1995-03-03 1996-03-01 Verfahren zur herstellung eines proteins
EP96906136A EP0813541B1 (en) 1995-03-03 1996-03-01 Process for producing a protein
PT96906136T PT813541E (pt) 1995-03-03 1996-03-01 Processo de producao de uma proteina
ES96906136T ES2199284T3 (es) 1995-03-03 1996-03-01 Procedimiento para producir una proteina.
CA002212125A CA2212125A1 (en) 1995-03-03 1996-03-01 Process for producing a protein
US08/875,125 US5834596A (en) 1995-03-03 1996-03-01 Process for purifying ApoA or ApoE
US09/129,720 US5990081A (en) 1995-03-03 1998-08-05 Purified APO A and APO E compounds and methods for using them
US09/444,816 US6506879B1 (en) 1995-03-03 1999-11-22 Purified Apo A and Apo E compounds and methods for using them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500778A SE9500778D0 (sv) 1995-03-03 1995-03-03 Process for producing a protein

Publications (1)

Publication Number Publication Date
SE9500778D0 true SE9500778D0 (sv) 1995-03-03

Family

ID=20397430

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9500778A SE9500778D0 (sv) 1995-03-03 1995-03-03 Process for producing a protein

Country Status (15)

Country Link
US (3) US5834596A (sv)
EP (1) EP0813541B1 (sv)
JP (1) JPH11501046A (sv)
AT (1) ATE240348T1 (sv)
AU (1) AU694623B2 (sv)
CA (1) CA2212125A1 (sv)
DE (1) DE69628148T2 (sv)
DK (1) DK0813541T3 (sv)
ES (1) ES2199284T3 (sv)
IL (1) IL117320A (sv)
NZ (1) NZ303325A (sv)
PT (1) PT813541E (sv)
SE (1) SE9500778D0 (sv)
WO (1) WO1996027608A1 (sv)
ZA (1) ZA961679B (sv)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
DE19859703B4 (de) * 1998-12-23 2009-10-29 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
WO2000059855A1 (en) * 1999-04-01 2000-10-12 Esperion Therapeutics, Inc. Ether compounds, compositions, and uses thereof
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU1384302A (en) * 2000-11-10 2002-05-21 Proteopharma Aps Apolipoprotein analogues
NZ532217A (en) * 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
BRPI0318046B8 (pt) 2003-01-23 2021-05-25 Esperion Therapeutics Inc compostos de hidroxila, seu usos, e composições farmacêuticas
TW200526778A (en) * 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
US20050176623A1 (en) * 2004-02-11 2005-08-11 Neil Wagle Non-invasive treatment of disease using amphipathic compounds
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
AU2006242651B2 (en) 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080199398A1 (en) * 2006-06-16 2008-08-21 Brewer H Bryan Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
AU2007272494B2 (en) 2006-07-14 2011-07-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
CN100586958C (zh) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 高纯度载脂蛋白a-i的制备方法
US8013122B2 (en) * 2006-12-20 2011-09-06 Kieu Hoang Method of purifying apolipoprotein A-1
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA2743139C (en) 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR101967411B1 (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
RS58275B1 (sr) * 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoproteinski kompleksi i njihova proizvodnja i upotrebe
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
KR102069395B1 (ko) 2011-12-12 2020-01-22 멜리어 파마슈티칼스 아이, 인코포레이티드 제i형 및 제ii형 당뇨병의 치료
JP2015519361A (ja) * 2012-05-31 2015-07-09 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 正電荷有機添加剤での処理によるタンパク質製剤におけるタンパク質−不純物複合体及び凝集体のレベルを低下させるための方法
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
IL250302B (en) 2014-07-31 2022-07-01 Uab Research Foundation Apoe mimetic peptides with high potency to clear plasma cholesterol
JP6940411B2 (ja) 2015-03-13 2021-09-29 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107033237B (zh) * 2017-05-11 2021-07-20 深圳市卫光生物制品股份有限公司 一种人血浆载脂蛋白a-i的分离纯化方法
MX2021015936A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Metodos para preparar acido bempedoico y composiciones del mismo.
CA3188232A1 (en) * 2020-08-10 2022-02-17 Kushee-Nidhi Kush KUMAR Antifungal matrix formed from peptide hydrogels

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6196998A (ja) 1984-10-16 1986-05-15 Mitsubishi Chem Ind Ltd ヒトアポリポプロテインａ−ｉ様蛋白の産生方法
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
SE462100B (sv) * 1985-08-08 1990-05-07 Perstorp Ab Komposition och dess anvaendning i ett tvaa- eller flerfassystem
EP0262651A3 (en) * 1986-09-30 1990-06-20 Union Carbide Corporation Isolation of enzyme values from solution
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
JP2561674B2 (ja) 1987-10-06 1996-12-11 三菱化学株式会社 蛋白質の産生方法
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
EP0497757B1 (en) * 1989-10-31 1994-06-22 Schering Corporation E. coli secretory strains
SE468881B (sv) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5733879A (en) * 1992-06-12 1998-03-31 N.V. Innogenetics, S.A. Peptides and proteins, process for their preparation and their use as cholesterol acceptors
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
JP3491917B2 (ja) * 1993-02-05 2004-02-03 メビオール株式会社 熱可逆性ハイドロゲル材料
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
JP3514514B2 (ja) * 1994-06-14 2004-03-31 財団法人化学及血清療法研究所 ヒト血漿からのアポリポ蛋白ａ−１の製造方法
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
WO1996004556A1 (en) * 1994-08-01 1996-02-15 Hsu James T Lipoprotein cholesterol assays
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5672685A (en) * 1995-10-04 1997-09-30 Duke University Source of apolipoprotein E and method of isolating apolipoprotein E
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein

Also Published As

Publication number Publication date
NZ303325A (en) 1998-12-23
IL117320A (en) 2001-06-14
JPH11501046A (ja) 1999-01-26
ATE240348T1 (de) 2003-05-15
ES2199284T3 (es) 2004-02-16
AU4960796A (en) 1996-09-23
DK0813541T3 (da) 2003-09-15
EP0813541B1 (en) 2003-05-14
DE69628148D1 (de) 2003-06-18
DE69628148T2 (de) 2004-01-08
AU694623B2 (en) 1998-07-23
US5990081A (en) 1999-11-23
EP0813541A1 (en) 1997-12-29
PT813541E (pt) 2003-09-30
ZA961679B (en) 1996-10-07
CA2212125A1 (en) 1996-09-12
IL117320A0 (en) 1996-06-18
US5834596A (en) 1998-11-10
WO1996027608A1 (en) 1996-09-12
US6506879B1 (en) 2003-01-14

Similar Documents

Publication Publication Date Title
SE9500778D0 (sv) Process for producing a protein
DE69736981D1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
ES2155477T3 (es) Purificacion cromatografica y procedimiento de separacion de acidos nucleicos.
PT83205B (pt) Metodo de purificacao e activacao de proteinas a partir de corpos de inclusao insoluveis
CA2182388A1 (en) Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
SE9603068D0 (sv) Process for purifying a protein
BG106768A (en) Process for the purification of pharmacologically active proteins by cation-exchange chromatography
ATE199742T1 (de) Verfahren zur herstellung von kalzium d- pantothenat
MY128271A (en) Purification method for (meth) acrylic acid
ATE50794T1 (de) Verfahren zur reinigung einer physiologisch aktiven substanz, die durch rekombinante dnatechnik hergestellt wurde.
ATE131490T1 (de) Verfahren zur herstellung von gereinigten albuminlösungen
FR2632302B1 (fr) Procede de recuperation d'acide citrique a partir d'une liqueur en contenant
DE602004020632D1 (de) Verfahren zur herstellung einer alpha-1-antitrypsinlösung
DE69902639T2 (de) Verbessertes verfahren zur herstellung von faktor viii
DE69902816T2 (de) Synthese von heteropolysäuren
HUP9901029A2 (hu) Eljárás rDSPA alfa1 előállítására
EP0446850A3 (en) Process for purifying recombinant human beta-interferon
ATE361320T1 (de) Monoklonaler antikörper gegen protein c inhibitor
RU95102320A (ru) Способ очистки сырого n-винилпирролид-2-она
KR910015699A (ko) 리포코틴의 정제방법
SE9301324D0 (sv) New method of treatment
ATE123495T1 (de) Verfahren zur herstellung 2-chlor-1,7- dihydropurin-6-on und verfahren zu dessen reinigung.
FI916021A0 (sv) Förfarande för rening av interferon
RU95103423A (ru) Способ выделения, очистки и концентрирования нуклеиновых кислот
GEP19971033B (en) Method of preparing lysozyme dimers